Semaglutide linked to fewer asthma attacks
A large UK records study associated semaglutide with nearly 40% fewer asthma attacks, but the conference result cannot show that the drug caused the difference.
The 60-second version
Semaglutide users had fewer asthma attacks in a large UK records analysis, but the result is observational and not proof of an asthma treatment.
Key points
- Four parallel studies each included about 20,000 to 22,000 people.
- Semaglutide showed the strongest reported association: nearly 40% fewer asthma attacks.
- COPD flare-ups were also reported about 20% lower with semaglutide.
- Randomized trials must test lung outcomes and separate drug effects from weight loss and confounding.
Verdict. A credible reason to run a trial, not a reason to change prescriptions today.
The signalWhat the researchers reported
A UK electronic-health-record study linked semaglutide with nearly 40% fewer asthma attacks. The same analysis reported about 20% fewer COPD flare-ups. Both figures describe associations in routine care, not effects established by random assignment.
The Imperial College London-led team presented the work at the European Respiratory Society Congress in Barcelona. It ran four parallel studies, each following roughly 20,000 to 22,000 people who started a GLP-1 receptor agonist or a sulfonylurea for an existing metabolic indication.
Study designA useful comparison, but not randomization
Using sulfonylurea starters as the comparison group is stronger than comparing GLP-1 users with everyone else: both groups had a clinical reason to receive glucose-lowering medicine. Yet doctors and patients still chose treatment in ordinary care, so the groups may differ in ways the records cannot fully capture.
| What the study can say | Attack rates differed between treatment groups after a real-world comparison. |
|---|---|
| What it cannot say | Semaglutide itself caused the difference or should be prescribed for asthma. |
| What comes next | Peer-reviewed methods and randomized trials with respiratory outcomes. |
Possible pathwaysWhy metabolism and airways may connect
Obesity and metabolic dysfunction can worsen airway disease through mechanical load, insulin resistance and inflammation. GLP-1 medicines can change weight and metabolic control, and may have anti-inflammatory effects. This study cannot tell whether one of those pathways, several together, or differences between patients explain the signal.
UncertaintyThe headline number needs a trial
Residual confounding remains possible from prescribing choices, disease severity, smoking, adherence and access to care. The result was a conference presentation; a full peer-reviewed report would be needed to inspect adjustment methods, follow-up, absolute attack rates and subgroup stability.
A large association can justify a clinical trial. It cannot substitute for one.
Practical meaningDo not change asthma treatment yet
People who already qualify for semaglutide for type 2 diabetes or obesity may eventually prove to gain an extra respiratory benefit. For now, the investigators say the finding should not change treatment on its own: continue prescribed inhalers and do not start a GLP-1 drug specifically for asthma or COPD outside current guidance.